Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple broadly neutralizing antibody lineages can co-exist and mature in the same germinal centers.

Cell reports·2026
Same author

Delayed type I interferon response and the subsequent out-of-sequence cytokine signal inhibit T cell induction in non-surviving Ebola virus-infected patients.

Frontiers in immunology·2026
Same author

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Lymphatic constraint of germinal centers optimizes protective antibody responses.

bioRxiv : the preprint server for biology·2025
Same author

Transient silencing of hypermutation preserves B cell affinity during clonal bursting.

Nature·2025
Same author

Hybrid metapopulation agent-based epidemiological models for efficient insight on the individual scale: A contribution to green computing.

Infectious Disease Modelling·2025

Related Experiment Video

Updated: Dec 2, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.1K

An Adaptive Control Scheme for Interleukin-2 Therapy.

Sahamoddin Khailaie1,2, Ghazal Montaseri1,3, Michael Meyer-Hermann1,2,4

  • 1Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany.

Iscience
|November 2, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces an adaptive IL-2 therapy to balance regulatory T cells (Tregs) and effector T cells (Tconvs) for autoimmune diseases. Mathematical modeling suggests minimal IL-2 dosage and Treg support can control immune responses and reduce side effects.

Keywords:
Biological SciencesImmunologyMathematical Bioscience

More Related Videos

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.0K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.8K

Related Experiment Videos

Last Updated: Dec 2, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.1K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.0K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.8K

Area of Science:

  • Immunology
  • Computational Biology
  • Pharmacology

Background:

  • Regulatory T cells (Tregs) and conventional T helper cells (Tconvs) maintain immune homeostasis.
  • An imbalance between Tregs and Tconvs is implicated in autoimmune and inflammatory diseases.
  • Interleukin-2 (IL-2) is a cytokine that influences both Treg and Tconv populations.

Purpose of the Study:

  • To design a minimal therapeutic IL-2 dosage using an adaptive control strategy.
  • To stabilize regulatory T cell populations and restrict inflammatory responses.
  • To investigate IL-2 therapy's impact on the Treg/Tconv balance through mathematical modeling.

Main Methods:

  • Development of a mechanistic mathematical model of immune cell dynamics.
  • Implementation of an adaptive control strategy for IL-2 dosage adjustments.
  • In silico simulations to evaluate therapeutic protocols and predict outcomes.

Main Results:

  • A minimal Treg population is essential to mitigate transient side effects of IL-2 on Tconvs.
  • The adaptive protocol allows for patient-specific dose adjustments based on immune kinetics.
  • Simulations demonstrated the potential of IL-2 therapy to restore immune balance.

Conclusions:

  • Adaptive IL-2 therapy offers a strategy to manage autoimmune and inflammatory conditions.
  • Mathematical modeling provides insights into optimizing IL-2 dosage for therapeutic benefit.
  • Combining IL-2 therapy with adoptive Treg transfer may further enhance treatment efficacy and limit side effects.